Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Loratadine Recommended to Be Approved as New Anti-allergic Drug
May 13, 2002
- Japanese, US, EU Patent Systems Need to Be Unified: Dr Fujino
May 13, 2002
- Abbott Aims at 20th Position in Japan: Mr Liepmann
May 13, 2002
- Debates on Healthcare Reform Start: Diet
May 13, 2002
- Wholesalers Should Take Firm Stance in Price Negotiations: FJPWA
May 13, 2002
- Original Makers to Take Tougher Stance against Patent Infringement
May 13, 2002
- BUSINESS NEWS IN BRIEF
May 13, 2002
- Number of Medical Accidents at Special Function Hospitals Totals over 15,000
May 13, 2002
- Fujisawa: Overseas Sales Exceed \150 Bil.
May 13, 2002
- SSP Licenses Spelear to Han All Pharm in South Korea
April 29, 2002
- Medical Facilities Run by Profit-making Firms to Be Discussed Again
April 29, 2002
- Vital-Net, Ohmori Yakuhin Tohoku to Merge in July
April 29, 2002
- Tokai Univ. Initiates Drug Discovery Project
April 29, 2002
- Animal Study Contracts Increasing: Huntingdon Life Sciences
April 29, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 29, 2002
- BUSINESS NEWS IN BRIEF
April 29, 2002
- Tokyo Katei Yakko Proposes New Distribution for Home Remedies
April 29, 2002
- WEBSITE NEWS
April 29, 2002
- LIFE Corporation to Expand Health Food Product Line
April 29, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
April 29, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…